Viral surveillance and subclinical viral infection in pediatric kidney transplantation

Pediatric Nephrology

Volumn 30, Issue 5, 2015, Pages 741-748

  Smith, Jodi M ^a   Dharnidharka, Vikas R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Kidney transplant; Pediatric; Subclinical infection; Viral surveillance

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ASYMPTOMATIC INFECTIONS; CHILD; EPIDEMIOLOGICAL MONITORING; GRAFT REJECTION; HUMAN; IMMUNOCOMPROMIZED PATIENT; KIDNEY TRANSPLANTATION; VIRUS DISEASES;

ASYMPTOMATIC INFECTIONS; CHILD; EPIDEMIOLOGICAL MONITORING; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; VIRUS DISEASES;

EID: 84939880209     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2866-8     Document Type: Article

References (60)

1. Husain S, Singh N (2002) The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 35:53–61
2. Dharnidharka VR, Stablein DM, Harmon WE (2004) Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 4:384–389
3. van der Bij W, Speich R (2001) Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 33(Suppl 1):S32–S37
4. Chapman JR (2010) The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation 89:644–645
5. Humar A, Michaels M (2006) American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6:262–274
6. Dharnidharka VR, Abdulnour HA, Araya CE (2011) The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment. Pediatr Nephrol 26:1763–1774
7. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J (2005) Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79:1277–1286
8. Hirsch HH, Randhawa P (2009) BK virus in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S136–S146
9. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333–360
10. Al Khasawneh E, Araya CE, Dharnidharka VR (2013) Missed viral surveillance testing visits associate with full blown viral diseases in children receiving kidney transplants. Pediatr Transplant 17:129–132
11. Gardner SD, Field AM, Coleman DV, Hulme B (1971) New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1:1253–1257
12. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR (2002) Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13:2145–2151
13. Hirsch HH, Steiger J (2003) Polyomavirus BK. Lancet Infect Dis 3:611–623
14. Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA (2007) BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2:1037–1042
15. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC (2010) BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 10:407–415
16. Weiss AS, Gralla J, Chan L, Klem P, Wiseman AC (2008) Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 3:1812–1819
17. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O Jr, Sarwal MM (2007) Subclinical cytomegalovirus and Epstein–Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 11:187–195
18. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA (2010) Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21:1579–1586
19. Bamoulid J, Courivaud C, Coaquette A, Chalopin JM, Gaiffe E, Saas P, Ducloux D (2013) Subclinical Epstein–Barr virus viremia among adult renal transplant recipients: incidence and consequences. Am J Transplant 13:656–662
20. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, Todo S, Green M (1997) Use of quantitative competitive PCR to measure Epstein–Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35:1612–1615
21. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein–Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517–1525
22. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA (1993) Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 56:88–96
23. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG (1995) Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 14:214–221
24. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE (2002) Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2:993–998
25. Silva A, Rodig N, Passerotti CP, Recabal P, Borer JG, Retik AB, Nguyen HT (2010) Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 184:1462–1467
26. Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, Starzl TE, Eastman R, Griffith BP, Hardesty RL, Bahnson HT, Hakala TR, Rosenthal JT (1985) Epstein–Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152:876–886
27. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR Jr (1996) Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein–Barr virus infection and immunosuppression. Transplantation 62:370–375
28. Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 13(Suppl 1):11–46
29. Wadowsky RM, Laus S, Green M, Webber SA, Rowe D (2003) Measurement of Epstein–Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 41:5245–5249
30. Hill CE, Harris SB, Culler EE, Zimring JC, Nolte FS, Caliendo AM (2006) Performance characteristics of two real-time PCR assays for the quantification of Epstein–Barr virus DNA. Am J Clin Pathol 125:665–671
31. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martin MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW (1998) Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66:1604–1611
32. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L (2007) Sustained Epstein–Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 13:343–348
33. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA (2008) Chronic high Epstein–Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8:442–445
34. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G (2009) Chronic high Epstein–Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 13:319–323
35. Nasimuzzaman M, Kuroda M, Dohno S, Yamamoto T, Iwatsuki K, Matsuzaki S, Mohammad R, Kumita W, Mizuguchi H, Hayakawa T, Nakamura H, Taguchi T, Wakiguchi H, Imai S (2005) Eradication of Epstein–Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther 11:578–590
36. Moudgil AMK, Moore T, Harmon WE, Dharnidharka VR (2012) Significance of persistent asymptomatic EBV viral load in pediatric renal transplant (TX) recipients. Am J Transplant 12(S3):445A
37. Tanaka E, Sato T, Ishihara M, Tsutsumi Y, Hisano M, Chikamoto H, Akioka Y, Dohno S, Maeda A, Hattori M, Wakiguchi H, Fujieda M (2011) Asymptomatic high Epstein–Barr viral load carriage in pediatric renal transplant recipients. Pediatr Transplant 15:306–313
38. Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schroder M, Billing H, Fichtner A, Feneberg R, Sander A, Kopf-Shakib S, Susal C, Tonshoff B (2013) Epidemiology and morbidity of Epstein–Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 56:84–92
39. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA (1995) Epstein–Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60:547–554
40. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein–Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83:2715–2722
41. Allen UD, Farkas G, Hebert D, Weitzman S, Stephens D, Petric M, Tellier R, Ngan B, Fecteau A, West L, Wasfy S (2005) Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant 9:450–455
42. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, Caligiuri MA (2003) Experimental treatment of Epstein–Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965–971
43. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA (2005) Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 5:2222–2228
44. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Lowenberg B, Cornelissen JJ (2002) Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364–4369
45. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL (2011) Monitoring infection with Epstein–Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 11:1058–1063
46. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD (2004) Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611–620
47. Villeneuve D, Brothers A, Harvey E, Kemna M, Law Y, Nemeth T, Gantt S (2013) Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant 17:80–85
48. Akalin E, Bromberg JS, Sehgal V, Ames S, Murphy B (2004) Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 4:148–149
49. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR (2008) Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46:840–846
50. Helantera I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P (2010) Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 10:2026–2032
51. Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA (2006) Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82:398–405
52. Ruttmann E, Geltner C, Bucher B, Ulmer H, Hofer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Muller LC (2006) Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81:1415–1420
53. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC (2003) Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 75:2064–2068
54. Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degre M, Fauchald P, Rollag H (2004) Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66:329–337
55. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H (2002) The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2:850–856
56. Reinke P, Prosch S, Kern F, Volk HD (1999) Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1:157–164
57. Gerstenkorn C, Robertson H, Mohamed MA, O'Donnell M, Ali S, Talbot D (2000) Detection of cytomegalovirus (CMV) antigens in kidney biopsies and transplant nephrectomies as a marker for renal graft dysfunction. Clin Chem Lab Med 38:1201–1203
58. Barzon L, Murer L, Pacenti M, Biasolo MA, Della Vella M, Benetti E, Zanon GF, Palu G (2009) Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. J Infect Dis 199:372–380
59. Laskin BL, Goebel J (2010) Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature. Pediatr Transplant 14:589–595
60. Smith F, Panek R, Kiberd BA (2009) Screening to prevent polyoma virus nephropathy in kidney transplantation: a cost analysis. Am J Transplant 9:2177–2179